Nice catch. Incidentally, GSK is paying a billion dollars plus possible milestone of $150K for a company's whose IDRX-42 is an ongoing phase I/Ib trial in patients with advanced GIST, gastrointestinal stromal tumors.

I mention this because I know of another company whose drug has done well in several Phase II and III trials for a wide variety of broad and lucrative indications. Wonder how much that company is worth?